Glucocorticoids and depression

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 4, 1999, Pages 597-614

  Steckler, Thomas ^a   Holsboer, Florian ^a   Reul, Johannes M H M ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressant; Corticosteroid; Depression; Glucocorticoid; HPA axis

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MOCLOBEMIDE; NEUROTRANSMITTER; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; DEPRESSION; DISEASE COURSE; DNA MODIFICATION; ENVIRONMENTAL FACTOR; FEEDBACK SYSTEM; HEREDITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROENDOCRINE SYSTEM; NONHUMAN; RAT; REMISSION; REVIEW; STRESS; SYMPTOM;

EID: 0033496443     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0046     Document Type: Article

References (138)

1. Gibbons J L. Cortisol secretion rate in depressive illness. Archives of General Psychiatry. 10:1964;572-575.
2. Rubin R T, Poland R E, Lesser I M. Neuroendocrine aspects of primary endogenous depression. Archives of General Psychiatry. 44:1987;328-336.
3. Nemeroff C B, Krishnan K R, Reed D. Adrenal gland enlargement in major depression. Archives of General Psychiatry. 49:1992;384-387.
4. Nemeroff C B, Widerlov E, Bissette G. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
5. Merchenthaler I. Corticotropin-releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides. 5:1984;53-69.
6. Swanson L W, Simmons D M. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. Journal of Comparative Neurology. 285:1989;413-435.
7. De Souza E B. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology. 20:1995;789-819.
8. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Reviews. 17:1996;187-205.
9. Owens M J, Nemeroff C B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Reviews. 43:1991;425-473.
10. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
11. Cullinan W E, Herman J P, Watson S J. Ventral subicular interactions with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis. Journal of Comparative Neurology. 332:1993;1-20.
12. Herman J P, Cullinam W E, Young E A. Selective forebrain fiber tract lesions implicate ventral hippocampal structures in tonic regulation of paraventricular nucleus corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) mRNA expression. Brain Research. 592:1992;228-238.
13. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biological Psychiatry. 46:1999;1480-1508.
14. Makino S, Gold P W, Schulkin J. Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis: comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Research. 657:1994;141-149.
15. Schulkin J, Gold P W, McEwen B S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology. 23:1998;219-243.
16. Arato M, Banki C M, Bissette G, Nemeroff C B. Elevated CSF CRH in suicide victims. Biological Psychiatry. 25:1989;355-359.
17. Banki C M, Bissette G, Arato M. Cerebrospinal fluid corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. American Journal of Psychiatry. 144:1987;874-877.
18. De Bellis M D, Gold P W, Geracioti T D Jr. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. American Journal of Psychiatry. 150:1993;656-657.
19. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Journal of Psychiatric Research. 33:1999;181-214.
20. Lee Y, Schulkin J, Davis M. Effect of corticosterone on the enhanced acoustic startle reflex by corticotropin-releasing factor. Brain Research. 666:1994;93-99.
21. Raadsheer F C, Hoogendijk W JG, Stam F C. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 60:1994;433-436.
22. De Kloet E R, Vreugdenhil E, Oitzl M S, Joels M. Brain corticosteroid receptor balance in health and disease. Endocrine Reviews. 19:1998;269-301.
23. McEwen B S, De Kloet E R, Rostene W H. Adrenal steroid receptors and actions in the nervous system. Physiological Reviews. 66:1986;1121-1188.
24. Reul J MHM, De Kloet E R. Two receptor systems for corticosterone in the rat brain: microdistribution and differential occupation. Endocrinology. 117:1985;2505-2512.
25. Modell S, Yassouridis A, Huber J, Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology. 65:1997;216-222.
26. Rupprecht R, Kornhuber J, Wodarz N. Disturbed glucocorticoid receptor autoregulation and corticotropin response to dexamethasone in depressives pretreated with methyrapone. Biological Psychiatry. 29:1991;1099-1109.
27. Holsboer F, Lauer C J, Schreiber W, Krieg J C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familiar risk for affective disorders. Neuroendocrinology. 62:1995;340-347.
28. Modell S, Lauer C J, Schreiber W. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familiar risk for affective disorders. Neuropsychopharmacology. 18:1998;253-262.
29. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 1999.
30. Lopez J F, Chalmers D T, Little K Y, Watson S j. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biological Psychiatry. 43:1998;547-573.
31. Härfstrand A, Fuxe K, Cintra A. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proceedings of the National Academy of Sciences of the USA. 83:1986;9779-9783.
32. Hadcock J R, Malbon C C. Regulation of β2-adrenergic receptors by 'permissive' hormones: glucocorticoids increase steady-state levels of receptor mRNA. Proceedings of the National Academy of Sciences of the USA. 85:1988;8415-8419.
33. Harrelson A L, Rostene W, McEwen B S. Adrenocortical steroids modify neurotransmitter-stimulated cyclic AMP accumulation in the hippocampus and limbic brain of the rat. Journal of Neurochemistry. 48:1987;1648-1655.
34. Quirarte G L, Roozendaal B, McGaugh J L. Glucocorticoid enhancement of memory storage involves noradrenergic activation in the basolateral amygdala. Proceedings of the National Academy of Sciences of the USA. 94:1997;14048-14053.
35. Roozendaal B, Williams C L, McGaugh J L. Glucocorticoid receptor activation in the rat nucleus of the solitary tract facilitates memory consolidation: involvement of the basolateral amygdala. European Journal of Neuroscience. 11:1999;1317-1323.
36. Lavicky J, Dunn A J. Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. Journal of Neurochemistry. 60:1993;602-612.
37. Schulz D W, Mansbach R S, Sprouse J. CP154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proceedings of the National Academy of Sciences of the USA. 93:1996;10477-10482.
38. van Bockstaele E J, Colago E EO, Valentino R J. Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites: substrate for the co-ordination of emotional and cognitive limbs of the stress response. Journal of Neuroendocrinology. 10:1998;743-757.
39. Biegon A, Israeli M. Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims. Brain Research. 442:1988;100-203.
40. De Paertmentier F, Cheetham S C, Crompton M R. Brain beta-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment. Psychopharmacology. 105:1991;283-288.
41. Klimek V, Rajkowska G, Luker S N. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology. 21:1999;69-81.
42. Piazza P V, Rouge-Pont F, Deminiere J M. Glucocorticoids have state dependent effects on the mesencephalic dopaminergic transmission. Proceedings of the National Academy of Sciences of the USA. 93:1996;8716-8720.
43. Schatzberg A F, Rothschild A J, Langlais P J. A corticosteroid/dopamine hypothesis for psychotic depression and related states. Journal of Psychiatric Research. 19:1985;57-64.
44. Schatzberg A F, Rothschild A J. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? American Journal of Psychiatry. 149:1992;733-745.
45. Chaouloff F. Regulation of 5-HT receptors by corticosteroids: where do we stand? Fundamental Clinical Pharmacology. 9:1995;219-233.
46. Deakin J FW, Graeff F G. 5-HT and mechanisms of defence. Journal of Psychopharmacology. 5:1991;305-315.
47. McAllister-Williams R H, Ferrier I N, Young A H. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychological Medicine. 28:1998;573-584.
48. Blier P, De Montigny C. Current advances in the treatment of depression. Trends in Pharmacology. 15:1994;220-226.
49. Barden N, Reul J MHM, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences. 18:1995;6-11.
50. Weiland N G, Orchinik M, McEwen B S. Chronic corticosterone treatment induces parallel changes in N -methyl- D -aspartate receptor subunit messenger RNA levels and antagonist binding sites in the hippocampus. Neuroscience. 78:1997;653-662.
51. Joels M, de Kloet E R. Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter release. Progress in Neurobiology. 43:1994;1-36.
52. Pavlides C, Watanabe Y, Margarinos A M, McEwen B S. Opposing roles of type I and type II adrenal steroid receptors in hippocampal long-term potentiation. Neuroscience. 68:1995;387-394.
53. Brown E S, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harvard Review of Psychiatry. 5:1998;239-246.
54. Cohen S I. Cushing's syndrome: a psychiatric study of 29 patients. British Journal of Psychiatry. 136:1980;120-124.
55. Kelly W F, Checkley S A, Bender D A, Mashiter K. Cushing's syndrome and depression - a prospective study of 26 patients. British Journal of Psychiatry. 142:1983;16-19.
56. Starkman M N, Schteingart D E, Schork M A. Cushing's syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Research. 19:1986;177-188.
57. Kelly W F, Kelly M J, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clinical Endocrinology. 45:1996;715-720.
58. Smyth J, Ockenfels M C, Porter L. Stressors and mood measured on a momentary basis are associated with salivary cortisol secretion. Psychoneuroendocrinology. 23:1998;353-370.
59. Plihal W, Krug R, Pietrowsky R. Corticosteroid receptor mediated effects on mood in humans. Psychoneuroendocrinology. 21:1996;515-523.
60. Kopell B S, Willner W K, Landi D. Cortisol effects on average evoked potentials, alpha-rhythm, time estimation, and two flash fusion threshold. Psychosomatic Medicine. 32:1970;39-49.
61. Wolkowitz O M, Reus V I, Weingartner H. Cognitive effects of corticosteroids. American Journal of Psychiatry. 147:1990;1297-1303.
62. Lupien S, Lecours A R, Lussier I. Basal cortisol levels and cognitive deficits in human aging. Journal of Neuroscience. 14:1994;2893-2903.
63. Lupien S J, Gillin C, Hauger R L. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behavioral Neuroscience. 119:1999;420-430.
64. Born J, Kern W, Fehm-Wolfsdorf G, Fehm H L. Cortisol effects on attentional processes in man as indicated by event-related potentials. Psychophysiology. 24:1987;286-292.
65. Lupien S J, Gaudreau S, Tchiteya B M. Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. Journal of Clinical Endocrinology and Metabolism. 82:1997;2070-2075.
66. Lupien S J, De Leon M, De Santi S. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience. 1:1998;69-73.
67. Keenan P A, Jacobson M W, Soleymani R M. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 47:1996;1396-1402.
68. Kirschbaum C, Wolf O T, May M. Stress and drug-induced elevation of cortisol levels impair explicit memory in healthy subjects. Life Sciences. 58:1996;1475-1483.
69. Newcomer J W, Craft S, Hershey T. Glucocorticoid-induced impairment in declarative memory performance in adult humans. Journal of Neuroscience. 14:1994;2047-2053.
70. Kitraki E, Karandrea D, Kittas C. Long-lasting effects of stress on glucocorticoid receptor gene expression in the rat brain. Neuroendocrinology. 69:1999;331-338.
71. Conrad C D, Galea L A, Kuroda Y, McEwen B S. Chronic stress impairs rat spatial memory performance on the Y maze, and this effect is blocked by tianeptin pretreatment. Behavioral Neuroscience. 110:1996;1321-1334.
72. Krugers H J, Douma B R, Andringa G. Exposure to chronic psychosocial stress and corticosterone in the rat: effects on spatial discrimination learning and hippocampal protein kinase Cgamma immunoreactivity. Hippocampus. 7:1997;427-436.
73. Luine V, Villegas M, Martinez C, McEwen B S. Repeated stress causes reversible impairments of spatial memory performance. Brain Research. 639:1994;167-170.
74. Kopp C, Vogel E, Rettori M C. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behavioural Pharmacology. 10:1999;73-83.
75. Sutanto W, Rosenfeld P, De Kloet E R, Levine S. Long-term effects of neonatal maternal deprivation and ACTH on hippocampal mineralocorticoid and glucocorticoid receptors. Developmental Brain Research. 92:1996;156-163.
76. Vasquez D M, van Oers H, Levine S, Akil H. Regulation of glucocorticoid and mineralocorticoid receptor mRNAs in the hippocampus of the maternally deprived infant rat. Brain Research. 731:1996;79-90.
77. Ellenbroek B A, van den Kroonenberg P T, Cools A R. The effects of an early stressful life event on sensorimotor gating in adult rats. Schizophrenia Research. 30:1998;251-260.
78. Zaharia M D, Kulczycki J, Shanks N. The effects of early postnatal stimulation on Morris water-maze acquisition in adult mice: genetic and material factors. Psychopharmacology. 128:1996;227-239.
79. Brown G M, Harris T. Disease, distress and depression. A comment. Journal of Affective Disorders. 26:1982;121-133.
80. Paykel E S, Myers J K, Dienelt M N. Life events and depression. A controlled study. Archives of General Psychiatry. 21:1969;753-760.
81. Kendler K S, Karkowski-Shuman L. Stressful life events and genetic liability to major depression: genetic control of exposure to the environment? Psychological Medicine. 27:1997;539-547.
82. Owens M J, Overstreet D, Knight D L. Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. Neuropsychopharmacology. 4:1991;87-93.
83. Ayensu W K, Pucilowsky O, Mason G A. Effects of chronic mild stress on serum complement activity, saccharin preference, and corticosterone levels in Flinders lines of rats. Physiology and Behavior. 57:1995;165-169.
84. Overstreet D H, Booth R H, Dana R. Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function. Psychopharmacology. 88:1986;129-130.
85. Overstreet D H, Daws L C, Schiller G D. Cholinergic/serotonergic interactions in hypothermia: implications for rat models of depression. Pharmacology Biochemistry and Behavior. 59:1998;777-785.
86. Shiromani P J, Overstreet D, Levy D. Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology. 1:1988;127-133.
87. Matthews K, Baldo B A, Markou A. Rewarding electrical brain stimulation: similar thresholds for Flinders Sensitive Line hypercholinergic and Flinders Resistant Line hypocholinergic rats. Physiology and Behavior. 59:1996;155-162.
88. Bushnell P J, Levin E D, Overstreet D H. Spatial working and reference memory in rats bred for autonomic sensitivity to cholinergic stimulation: acquisition, accuracy, speed, and effects of cholinergic drugs. Neurobiology of Learning and Memory. 63:1995;116-132.
89. Schiller G D, Daws L C, Overstreet D H, Orbach J. Lack of anxiety in an animal model of depression with genetic muscarinic supersensitivity. Brain Research Bulletin. 26:1991;433-435.
90. Abel E L. Behavior and corticosteroid response of Maudsley reactive and nonreactive rats in the open field and forced swimming test. Physiology and Behavior. 50:1991;151-153.
91. Castanon N, Dulluc J, Le Moal M, Mormede P. Maturation of the behavioral and neuroendocrine differences between the Roman rat lines. Physiology and Behavior. 55:1994;775-782.
92. Liebsch G, Montkowski A, Holsboer F, Landgraf R. Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behavioural Brain Research. 94:1998;301-310.
93. Liebsch G, Linthorst A C, Neumann I D. Behavioral, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high- and low-anxiety-related behavior. Neuropsychopharmacology. 19:1998;381-396.
94. Landgraf R, Wigger A, Holsboer F, Neumann I D. Hyper-reactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behavior. Journal of Neuroendocrinology. 11:1999;405-407.
95. Neumann I D, Wigger A, Liebsch G. Increased basal activity of the hypothalamo-pituitary-adrenal axis during pregnancy in rats bred for high anxiety-related behaviour. Psychoneuroendocrinology. 23:1998;449-463.
96. Cole T J, Blendy J A, Monaghan P. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffine cell development and severely retards lung maturation. Genes and Development. 9:1995;1608-1621.
97. Oitzl M S, De Kloet E R, Joels M. Spatial learning deficits in mice with a targeted glucocorticoid receptor gene disruption. European Journal of Neuroscience. 9:1997;2284-2296.
98. Steckler T, Weis C, Sauvage M. Disrupted allocentric but preserved egocentric spatial learning in transgenic mice with impaired glucocorticoid receptor function. Behavioural Brain Research. 100:1999;77-89.
99. Montkowski A, Barden N, Wotjak C. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. Journal of Neuroendocrinology. 7:1995;841-845.
100. Rochford J, Beaulieu S, Rousse I. Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: effects of diazepam and FG-7142. Psychopharmacology. 132:1997;145-152.
101. Tronche F, Kellendonk K, Kretz O. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nature Genetics. 23:1999;99-103.
102. Richard D, Chapdelaine S, Deshaies Y. Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct. American Journal of Physiology. 265:1993;146-150.
103. Steckler T, Holsboer F. Enhanced conditioned approach responses in transgenic mice with impaired glucocorticoid receptor function. Behavioural Brain Research. 102:1999;151-163.
104. Spanagel R, Stöhr T, Barden N, Holsboer F. Morphine-induced locomotor and neurochemical stimulation is enhanced in transgenic mice with impaired glucocorticoid receptor function. Journal of Neuroendocrinology. 8:1996;93-97.
105. Pepin M C, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature. 355:1992;725-728.
106. Stec I, Barden N, Reul J MHM, Holsboer F. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. Journal of Psychiatric Research. 28:1994;1-5.
107. Barden N, Stec I SM, Montkowski A. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology. 66:1997;597-612.
108. Karanth S, Linthorst A CE, Stalla G K. Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology. 138:1997;3476-3485.
109. Dijkstra I, Tilders F JH, Aguilera G. Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucocorticoid receptor function. Journal of Neuroscience. 18:1998;3909-3918.
110. Linthorst A CE, Flachskamm C, Barden N. Glucocorticoid receptor impairment alters CNS responses to a psychological stressor: an in vivo microdialysis study in transgenic mice. European Journal of Neuroscience. 12:2000;283-291.
111. Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. Journal of Affective Disorders. 4:1982;93-101.
112. Greden J F, Gardner R, King D. Dexamethasone suppression test in antidepressant treatment of melancholia. Archives of General Psychiatry. 40:1983;493-500.
113. Holsboer F, Steiger A, Maier W. Four cases of reversion to abnormal dexamethasone suppression test response as indicator of clinical relapse: a preliminary report. Biological Psychiatry. 18:1983;911-916.
114. Ribeiro S CM, Tandon R, Grunhaus L, Greden J F. The DST as a predictor of outcome in depression: a meta-analysis. American Journal of Psychiatry. 150:1993;1618-1629.
115. Heuser I J, Schweiger U, Gotthardt U. Pituitary-adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and in normal controls. American Journal of Psychiatry. 153:1996;93-99.
116. Holsboer F, Gerken A, Stalla G K, Müller O A. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. American Journal of Psychiatry. 144:1987;229-231.
117. Holsboer-Trachsler E, Hemmeter U, Stohler R. The dexamethasone-hCRH stimulation test and cognitive performance during antidepressive treatment with trimipramine. European Neuropsychopharmacology. 1:1991;338-340.
118. Holsboer-Trachsler E, Hemmeter U, Hatzinger M. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - neurobiological and psychometric assessment of course. Journal of Psychiatric Research. 28:1994;381-399.
119. Zobel A W, Yassouridis A, Frieboes R M, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. American Journal of Psychiatry. 156:1999;949-951.
120. De Bellis M D, Gold P W, Geracioti T D Jr. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. American Journal of Psychiatry. 150:1993;656-657.
121. Labrid C, Mocaer E, Kamoun A. Neurochemical and pharmacological properties of tianeptine, a novel antidepressant. British Journal of Psychiatry. 160:1992;56-60.
122. Delbende C, Contesse V, Mocaer E. The novel of antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. European Journal of Pharmacology. 202:1991;391-396.
123. Defrance R, Marey C, Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clinical Neuropharmacology. 11:1988;S74-S82.
124. Reul J MHM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology. 133:1993;312-320.
125. Reul J MHM, Labeur M S, Grigoriadis D E. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology. 60:1994;509-519.
126. Laakmann G, Schoen H W, Blaschke D, Wittmann M. Dose dependent growth hormone, prolactin and cortisol stimulation after i.v. administration of desimipramine in human subjects. Psychoneuroendocrinology. 10:1985;83-93.
127. Asnis G M, Sanderson W C, van Praag H M. Cortisol response to intramuscular desipramine in patients with major depression and normal control subjects: a replication study. Psychiatry Research. 44:1992;237-250.
128. Steiger A, Gerken A, Benkert O, Holsboer F. Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: studies on depressed patients and normal controls. European Neuropsychopharmacology. 3:1993;117-126.
129. Golden R N, Ekstrom D, Brown T M. Neuroendocrine effects on intravenous clomipramine in depressed patients and healthy subjects. American Journal of Psychiatry. 149:1992;1168-1175.
130. Daffner B C, Laakmann G, Baghai T. Influences of venaflaxine on growth hormone (GH) and other hormones in healthy subjects. Neuropsychopharmacology. 9:1993;100S-101S.
131. Brady L S, Whitfield H J Jr, Fox R J. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in the rat brain. Journal of Clinical Investigation. 87:1991;831-837.
132. Brady L S, Gold P W, Herkenham M. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Research. 572:1992;117-125.
133. Shimoda K, Yamada N, Ohi K. Chronic administration of tricyclic antidepressants suppresses hypothalamic-pituitary-adrenocortical activity in male rats. Psychoneuroendocrinology. 13:1988;431-440.
134. Seckl J R, Finck G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology. 55:1992;621-626.
135. Kitayama I, Janson A M, Cintra A. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. Journal of Neural Transmission. 73:1988;191-203.
136. Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry. 29:1996;12-22.
137. Sillaber I, Montkowski A, Landgraf R. Enhanced morphine-induced behavioural effects and dopamine release in the nucleus accumbens in a transgenic mouse model of impaired glucorticoid (type II) receptor function: influence of long-term treatment with the antidepressant moclobemide. Neuroscience. 85:1998;415-425.
138. Wolkowitz O M, Reus V I, Chan T. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biological Psychiatry. 45:1999;1070-1074.